LFSC vs. IDNA
Compare and contrast key facts about F/m Emerald Life Sciences Innovation ETF (LFSC) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).
LFSC and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019.
Performance
LFSC vs. IDNA - Performance Comparison
Loading graphics...
LFSC vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | -4.45% | 56.54% | -6.02% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 11.45% | 17.26% | -5.77% |
Returns By Period
In the year-to-date period, LFSC achieves a -4.45% return, which is significantly lower than IDNA's 11.45% return.
LFSC
- 1D
- 6.16%
- 1M
- -3.82%
- YTD
- -4.45%
- 6M
- 17.66%
- 1Y
- 55.83%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
IDNA
- 1D
- 0.48%
- 1M
- -5.56%
- YTD
- 11.45%
- 6M
- 20.68%
- 1Y
- 48.06%
- 3Y*
- 9.03%
- 5Y*
- -7.93%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
LFSC vs. IDNA - Expense Ratio Comparison
LFSC has a 0.54% expense ratio, which is higher than IDNA's 0.47% expense ratio.
Return for Risk
LFSC vs. IDNA — Risk / Return Rank
LFSC
IDNA
LFSC vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LFSC | IDNA | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.93 | 1.75 | +0.18 |
Sortino ratioReturn per unit of downside risk | 2.65 | 2.40 | +0.25 |
Omega ratioGain probability vs. loss probability | 1.33 | 1.29 | +0.04 |
Calmar ratioReturn relative to maximum drawdown | 3.20 | 3.66 | -0.46 |
Martin ratioReturn relative to average drawdown | 8.96 | 11.65 | -2.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LFSC | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.93 | 1.75 | +0.18 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.28 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.94 | 0.11 | +0.84 |
Correlation
The correlation between LFSC and IDNA is 0.72, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
LFSC vs. IDNA - Dividend Comparison
LFSC has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 1.06%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.06% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Drawdowns
LFSC vs. IDNA - Drawdown Comparison
The maximum LFSC drawdown since its inception was -29.74%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for LFSC and IDNA.
Loading graphics...
Drawdown Indicators
| LFSC | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.74% | -68.26% | +38.52% |
Max Drawdown (1Y)Largest decline over 1 year | -16.25% | -12.11% | -4.14% |
Max Drawdown (5Y)Largest decline over 5 years | — | -68.26% | — |
Current DrawdownCurrent decline from peak | -11.08% | -45.05% | +33.97% |
Average DrawdownAverage peak-to-trough decline | -8.25% | -36.05% | +27.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.80% | 3.81% | +1.99% |
Volatility
LFSC vs. IDNA - Volatility Comparison
F/m Emerald Life Sciences Innovation ETF (LFSC) has a higher volatility of 10.35% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 9.54%. This indicates that LFSC's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LFSC | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.35% | 9.54% | +0.81% |
Volatility (6M)Calculated over the trailing 6-month period | 19.97% | 18.22% | +1.75% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.24% | 27.75% | +1.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.31% | 28.53% | +0.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.31% | 29.68% | -0.37% |